Stock Financial Ratios, Dividends, Split History

WLTW / Willis Towers Watson Public Limited Company financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price158.04
Volume415,300.00
Market Cap ($M)20,687.01
Enterprise Value ($M)24,472.84
Book Value ($M)10,672.00
Book Value / Share80.95
Price / Book1.94
NCAV ($M)-5,776.00
NCAV / Share-43.81
Price / NCAV-3.60
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 136,000,000
Common Shares Outstanding 132,216,177
Weighted Average Number Of Shares Outstanding Basic 135,000,000
Weighted Average Number Diluted Shares Outstanding Adjustment 1,000,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.02
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets34,212.00
Liabilities23,382.00
Quick Ration/a
Current Ratio1.11
Income Statement (mra) ($M)
Sales Revenue Net8,202,000,000.00
Other Sales Revenue Net86,000,000.00
Sales Revenue Services Net8,116,000,000.00
Dispositions Revenuespriorto Sales54,000,000.00
Reimbursement Revenue98,000,000.00
Revenues8,202,000,000.00
Revenue From Group Undertakings0.00
Operating Income738.00
Net Income592.00
Earnings Per Share Diluted4.18
Earnings Per Share Basic4.21
Cash Flow Statement (mra) ($M)
Cash From Operations862.00
Cash from Investing-335.00
Cash from Financing-335.00
Identifiers and Descriptors
CUSIPG96629103
Central Index Key (CIK)1140536
Related CUSIPS
G96629903 G96629953 0G9662910

Split History

Stock splits are used by Willis Towers Watson Public Limited Company to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2018 Update

2018-05-15 seekingalpha
David Abrams’ 13F portfolio value increased this quarter from $2.97B to $3.19B. The number of positions remained steady at 20. (710-3)

Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q1 2018 Update

2018-05-09 seekingalpha
The portfolio continues to be very concentrated with the top five positions accounting for ~30% of the 13F portfolio. (519-1)

Willis Towers Watson Public Limited 2018 Q1 - Results - Earnings Call Slides

2018-05-07 seekingalpha
The following slide deck was published by Willis Towers Watson Public Limited in conjunction with their 2018 Q1 earnings call. (1-0)

Willis Towers (WLTW) Q1 Earnings Surpass, Guidance Intact

2018-05-07 zacks
Willis Towers Watson Public Limited Company (WLTW - Free Report) reported first-quarter 2018 adjusted earnings of $2.71 per share, surpassing the Zacks Consensus Estimate of $2.63 by 3%. However, the bottom line declined 26.9% year over year. (45-0)

Willis Towers (WLTW) Q1 Earning & Revenues Beats Estimates

2018-05-07 zacks
Have you been eager to see how Willis Towers Watson Public Limited Company (WLTW - Free Report) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this insurance broker company’s earnings release this morning. An Earnings Beat Willis Towers Watson came out with operating earnings of $2.71 per share, which beat the Zacks Consensus Estimate of $2. (15-0)

CUSIP: G96629103